Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma
Abstract Background Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed...
Saved in:
| Main Authors: | Maximilian Linxweiler, Jan Philipp Kühn, Christian Neubert, Fadi Khreish, Benedikt Balensiefer, Mathias Wagner, Bernhard Schick |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-05-01
|
| Series: | Journal of Otolaryngology - Head and Neck Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40463-022-00572-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase
by: Ken Saijo, et al.
Published: (2025-04-01) -
Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab
by: Jared Weiss, et al.
Published: (2024-12-01) -
Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck
by: Allen M. Chen, et al.
Published: (2025-03-01) -
Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01) -
Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck
by: Shogen Boku, et al.
Published: (2025-07-01)